🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Strides Pharma Science Limited STAR NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.strides.com
Company Profile ↓
₹1,069.00
+23.39% 1Y
Mkt Cap₹9,853.26 Cr
P/E2.74
P/B3.19
Div. Yield0.37%
52W High₹1,188.10
52W Low₹793.55
Book Value₹337.15
EPS (TTM)₹390.50

Company Overview

Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, and internationally. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, gels, powders, solids, ointments, and creams. It also develops branded generics products for the treatment of chronic therapies, including women's health, central nervous system, cardiovascular, diabetes, dermatology, and probiotics under the Renerve, Unibrol, Combiart, Duotab, and Vitafer brands; and anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for institutional business. The company was formerly known as Strides Shasun Limited and changed its name to Strides Pharma Science Limited in July 2018. The company was incorporated in 1990 and is based in Bengaluru, India.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 17.9%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 21.0%.

Consistent Profit Growth

Net profit has compounded at 124.8% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 10.4% CAGR over the past five years.

Reasonable Valuation

Trades at a P/E of 2.7, below the sector median of 40.0.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Mar 2026 Revenue of ₹4,858.68 Cr (+6.4% YoY); net profit ₹556.19 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +6.4%, earnings -84.5%.
  • 5-Year Trend Long-term compounding — revenue CAGR 10.4%, profit CAGR 124.8%.

Growth & Price Performance

Compounded Sales Growth

5 Years:10.43%
1 Year:6.43%

Compounded Profit Growth

5 Years:124.83%
1 Year:-84.52%

Stock Price Performance

1 Year:+23.39%
6 Months:+13.50%
3 Months:+7.56%
1 Month:-1.50%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed
52-Week Range 70% of range
₹793.55 ₹1,188.10
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMAAbove
  • RSI (14)43.65 · Neutral
Price Performance
1M-1.50%
3M+7.56%
6M+13.50%
1Y+23.39%
Valuation vs Sector

P/E of 2.74 is below the sector median of 39.97 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Healthy ROCE of 21.0%.
  • Compounding revenue at 10.4% over 5 years.
  • Profit CAGR of 124.8% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
2.74
Industry PE
39.97
Forward P/E
11.21
PEG Ratio
-
Book Value
₹337.15
Price to Book
3.19
P/S
2.04
EV/EBITDA
12.41
Dividend Yield
0.37%

Growth (CAGR)

Revenue 5Y
10.43%
Profit 5Y
124.83%
Revenue (YoY)
6.43%
Earnings (YoY)
-84.52%

Profitability & Returns

ROCE
21.01%
ROE
17.90%
ROA
8.03%
Profit Margin
11.45%
Op Margin
14.88%
Gross Margin
59.69%
EPS (Latest Qtr)
₹13.77
EPS (TTM)
₹390.50

Balance Sheet & Liquidity

Debt/Equity
0.57
Quick Ratio
0.68
Current Ratio
1.25
Debt
₹1,757.98 Cr
Total Assets
₹6,927.23 Cr
Current Assets
₹3,613.34 Cr
Working Capital
₹717.85 Cr

Ownership

Promoter Holding
30.83%
Chg in Prom Hold
2.92%
FII / Inst Holding
29.20%
Chg in FII Hold
-0.05%

Financial Snapshot

Enterprise Value
₹9,853.26 Cr
Total Revenue (TTM)
₹4,858.68 Cr
EBITDA
₹1,049.63 Cr
Free Cash Flow
₹284.58 Cr
Operating Cash Flow
₹702.52 Cr
Shares Outstanding
₹9.22 Cr
Gross Margin
59.69%
Payout Ratio
6.63%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 STAR Strides Pharma Science Limited NSEPHARMA 1,069.00 2.74 ₹9,853.26 Cr 0.37% 21.01% 17.90% 10.43% 124.83%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,948.80 40.77 ₹4.68 L Cr 0.83% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 7,315.50 75.61 ₹1.94 L Cr 0.44% 18.96% 15.32% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,952.20 87.70 ₹1.68 L Cr 0.78% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,981.00 66.51 ₹1.29 L Cr 0.23% 19.79% 20.48% 15.33% 33.34%
6 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,440.10 22.07 ₹1.16 L Cr 0.90% 14.86% 11.27% 7.23% 11.45%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,137.40 22.71 ₹1.14 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,494.30 21.42 ₹1.14 L Cr 0.72% 28.42% 23.76% 19.10% 131.46%
9 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 1,099.00 99.82 ₹1.07 L Cr 0.18% 12.57% 13.42% 22.37% 9.34%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 986.00 Cr930.00 Cr999.00 Cr1,006.00 Cr1,044.00 Cr1,054.00 Cr1,167.00 Cr1,153.67 Cr1,190.39 Cr1,119.74 Cr1,221.00 Cr1,194.65 Cr1,323.47 Cr
Cost of Revenue -------480.12 Cr498.97 Cr444.28 Cr-462.94 Cr536.25 Cr
Gross Profit -------673.54 Cr691.43 Cr675.45 Cr-731.71 Cr787.23 Cr
Operating Expenses 871.00 Cr796.00 Cr889.00 Cr876.00 Cr874.00 Cr866.00 Cr983.00 Cr511.65 Cr522.42 Cr506.26 Cr990.00 Cr546.38 Cr600.77 Cr
Operating Income 54.00 Cr74.00 Cr51.00 Cr80.00 Cr121.00 Cr141.00 Cr136.00 Cr161.89 Cr169.01 Cr169.19 Cr181.00 Cr185.32 Cr186.46 Cr
EBITDA 115.00 Cr134.00 Cr111.00 Cr129.00 Cr169.00 Cr188.00 Cr184.00 Cr214.45 Cr205.56 Cr218.39 Cr231.00 Cr339.48 Cr242.88 Cr
Interest Expense 81.00 Cr76.00 Cr79.00 Cr70.00 Cr71.00 Cr73.00 Cr74.00 Cr52.18 Cr50.32 Cr47.46 Cr46.00 Cr43.38 Cr41.58 Cr
Pretax Income -7.00 Cr0-157.00 Cr70.00 Cr23.00 Cr3,369.00 Cr86.00 Cr113.84 Cr106.38 Cr122.04 Cr153.00 Cr245.47 Cr148.05 Cr
Tax Provision -7.42 Cr07.85 Cr16.10 Cr12.65 Cr33.69 Cr13.76 Cr23.80 Cr20.76 Cr16.45 Cr21.42 Cr37.35 Cr18.77 Cr
Net Income -14.00 Cr-9.00 Cr-149.00 Cr54.00 Cr10.00 Cr3,350.00 Cr72.00 Cr87.95 Cr82.19 Cr99.61 Cr132.00 Cr202.11 Cr126.94 Cr
Diluted EPS -1.06-0.79-14.545.401.98364.697.819.558.9210.8113.8421.9213.77

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 1,196.00 Cr2,861.00 Cr2,755.00 Cr2,845.00 Cr2,178.00 Cr2,752.00 Cr3,316.00 Cr-3,607.67 Cr3,730.02 Cr4,565.34 Cr4,858.68 Cr
Cost of Revenue --------1,745.85 Cr1,883.55 Cr1,979.97 Cr1,958.73 Cr
Gross Profit --------1,861.82 Cr1,846.47 Cr2,585.37 Cr2,899.95 Cr
Operating Expenses 967.00 Cr2,486.00 Cr2,228.00 Cr2,448.00 Cr1,982.00 Cr2,338.00 Cr2,779.00 Cr-1,718.94 Cr1,525.39 Cr1,974.82 Cr2,177.06 Cr
Operating Income 165.00 Cr243.00 Cr401.00 Cr244.00 Cr80.00 Cr240.00 Cr331.00 Cr-142.88 Cr321.08 Cr610.55 Cr722.89 Cr
EBITDA 229.00 Cr374.00 Cr527.00 Cr398.00 Cr197.00 Cr414.00 Cr537.00 Cr-174.64 Cr344.40 Cr928.03 Cr1,049.63 Cr
Interest Expense 47.00 Cr168.00 Cr183.00 Cr196.00 Cr79.00 Cr156.00 Cr150.00 Cr-217.59 Cr238.51 Cr248.85 Cr178.54 Cr
Pretax Income 992.00 Cr137.00 Cr509.00 Cr690.00 Cr303.00 Cr42.00 Cr289.00 Cr--286.20 Cr-114.79 Cr486.92 Cr668.69 Cr
Tax Provision 148.80 Cr42.47 Cr61.08 Cr6.90 Cr-27.27 Cr11.34 Cr31.79 Cr--55.30 Cr29.11 Cr77.52 Cr94.19 Cr
Net Income 844.00 Cr95.00 Cr446.00 Cr684.00 Cr330.00 Cr31.00 Cr258.00 Cr--202.63 Cr-70.61 Cr3,593.45 Cr556.19 Cr
Diluted EPS 141.7812.1544.7174.2536.274.0629.93-51.28-22.49-7.76390.50-

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 2,475.00 Cr7,410.00 Cr8,046.00 Cr6,585.00 Cr7,807.00 Cr6,131.00 Cr6,969.00 Cr-6,638.42 Cr5,839.76 Cr6,048.73 Cr6,927.23 Cr
Current Assets --------3,245.94 Cr2,972.49 Cr3,101.68 Cr3,613.34 Cr
Cash & Equivalents --------303.50 Cr161.02 Cr112.56 Cr188.70 Cr
Inventory --------1,146.51 Cr1,126.24 Cr1,277.57 Cr1,634.79 Cr
Receivables --------1,299.40 Cr1,141.87 Cr1,202.94 Cr1,288.96 Cr
Total Liabilities --------4,465.54 Cr3,768.05 Cr3,462.26 Cr3,777.89 Cr
Current Liabilities --------2,990.20 Cr2,879.26 Cr2,591.52 Cr2,895.49 Cr
Long Term Debt --------1,139.79 Cr671.50 Cr571.24 Cr552.32 Cr
Total Debt 892.00 Cr3,542.00 Cr3,700.00 Cr2,520.00 Cr3,221.00 Cr2,235.00 Cr2,348.00 Cr-3,029.57 Cr2,516.86 Cr1,879.63 Cr1,757.98 Cr
Total Equity 1,145.00 Cr2,658.00 Cr2,748.00 Cr2,464.00 Cr2,649.00 Cr2,528.00 Cr2,777.00 Cr-2,212.26 Cr2,125.57 Cr2,551.83 Cr3,107.57 Cr
Shares Outstanding --------9.03 Cr9.19 Cr9.22 Cr9.22 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 83.00 Cr73.00 Cr288.00 Cr187.00 Cr60.00 Cr205.00 Cr481.00 Cr-44.41 Cr701.07 Cr684.37 Cr702.52 Cr
Investing Cash Flow 50.00 Cr-2,205.00 Cr-1,222.00 Cr570.00 Cr-145.00 Cr1,321.00 Cr-522.00 Cr-302.47 Cr-150.25 Cr-89.69 Cr-173.04 Cr
Financing Cash Flow -421.00 Cr2,944.00 Cr338.00 Cr-1,016.00 Cr194.00 Cr-1,709.00 Cr-16.00 Cr--213.92 Cr-693.32 Cr-642.58 Cr-453.41 Cr
Capital Expenditure -240.00 Cr-366.00 Cr-674.00 Cr-399.00 Cr-316.00 Cr-147.00 Cr-293.00 Cr--94.94 Cr-118.15 Cr-247.50 Cr-417.94 Cr
Free Cash Flow -157.00 Cr-293.00 Cr-386.00 Cr-212.00 Cr-256.00 Cr58.00 Cr188.00 Cr--50.53 Cr582.91 Cr436.88 Cr284.58 Cr
Net Change in Cash -288.00 Cr812.00 Cr-596.00 Cr-259.00 Cr110.00 Cr-184.00 Cr-56.00 Cr-132.96 Cr-142.51 Cr-47.90 Cr76.07 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % --------51.6%49.5%56.6%59.7%
Operating Margin % 13.8%8.5%14.6%8.6%3.7%8.7%10.0%-4.0%8.6%13.4%14.9%
Net Margin % 70.6%3.3%16.2%24.0%15.2%1.1%7.8%--5.6%-1.9%78.7%11.4%
ROE % 73.7%3.6%16.2%27.8%12.5%1.2%9.3%--9.2%-3.3%140.8%17.9%
ROCE % --------3.9%10.8%17.7%17.9%

Shareholding Pattern

Insiders
30.83%
Institutions
29.20%
Public Float
42.21%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for STAR

Google News Wed, 15 Jul 2026

33 Undervalued Stocks to Buy Before the Market Catches On - Morningstar

<a href="https://news.google.com/rss/articles/CBMiigFBVV95cUxNLXBabV9kS2hvcXc4UWthYkFUVm9udnlNZGZZMndBb0V3cjZfYmhlWmJoNC1nZkl1d2RreHUzbTkyRkxpcHFZUFl3d2dFQWtPR3d0ekw3b3ZPZUF2Y3I5U3pDcWtneTZvekxUbXdWRS1uSEhJYUpIWkM5NFRwVjZna1RtSU1OcVhtaGc?oc…

Google News Mon, 13 Jul 2026

The 2026 All-Star Stock Report, Part 1 - Baseball Prospectus

<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxNVWxvOC0zMmNCS0VQbUxIWS1MVlVUaTZqWXZGYTVqaFcxMHhIMW10dGJsT1ZGamp6UDZxbVpncjdqdHhNWXA4dnYwVUVjTGVkNzhRV1YzZVBUeHVONmF2aHV6WFNSVks4SkN4TFRQSkN1MFZsYUExODd6RmpqNVI5U3dFOGVORHA1MDdSUX…

Google News ue, 14 Jul 2026

2 Growth Stocks with All-Star Potential and 1 Facing Headwinds - StockStory

<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxPTVllV2R0N1ZUalVJNkFZSm1SVlNkUkJSY29ab09rUnhNNjBtUUludmZmanlnNXNhUHB5cHhfLTA2ODNHLXgxWk5iV045dElrMnd1SHljQjZyeW10T1FUamFFMEVPRG5lZFQ2MnBwR2s2RFRERk5EekhpWVlUeUxEVEc4cmttcFc5dFlXUT…

Google News Mon, 13 Jul 2026

3 Growth Stocks with All-Star Potential - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxPRjVHT015ZG5XOTBiMkwyLVJyc0h5WjMyZEFUdElnUDBtTTNtOEdPaGFyQ3p2dmdvdXZHaElObjJrUTV3UEVMOW12LU5DbkdsUU4zbjJuc0x0WF9fS2lPSXhEZlpTQ3o1SlBhVnVQODdhQjByVm84a0l1d0lleG9TYVdyRjZCVDRUN0stLU…

Google News Wed, 15 Jul 2026

SK Hynix shares jump nearly 13%, tracking US stock gains - The Star

<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxNbFhPdHpRZ1V5SklNNUJzaTkzSDFWWnpQNl9YNkY0c0U2dVBWaFQ3RjdRekVXUWkyYnRrVnlFb1FNcDBvVDlvOFV6M2xkYWVOYXRBR0pNRUFnWUVMSnFyalZnYThWYk1IN1N0M0o4a3I2VHR3SGI0NVNBZmRFbEU3b3R0XzN6ajU1UktobX…

Google News Mon, 13 Jul 2026

Healthcare Looks Ready to Star in Rotation Trade: Taking Stock - Bloomberg.com

<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxNRlBZdy1wWUFnVVJ0YnFzeFpEV0ItamdocEcxenBFNVdCT3RqMW9Qd3ViV08zeUtOVXJja1ExcUlLbXdjcEJuVmhxMnlVT1FYMF9ZTWJmb3F6Z2lmRlV6RUg5b1NFUmF6dllMVzFFUWJzRzItYmNMenpBWFJOeTZ1NGV6MWlsZUQweHozcm…

STAR — Frequently Asked Questions

What is the current share price of Strides Pharma Science Limited (STAR)?

As of 2026-07-15 09:52 IST, Strides Pharma Science Limited (STAR) trades at ₹1,069.00 on NSE. Its 52-week range is ₹793.55 to ₹1,188.10.

What is the market capitalisation of STAR?

Strides Pharma Science Limited (STAR) has a market capitalisation of ₹9,853.26 Cr on NSE.

What is the P/E ratio of STAR?

STAR trades at a trailing price-to-earnings (P/E) ratio of 2.74. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 3.19.

Does STAR pay a dividend?

Strides Pharma Science Limited (STAR) currently offers a dividend yield of 0.37%.

What is the return on equity (ROE) of STAR?

STAR has a return on equity (ROE) of 17.90%. Its return on capital employed (ROCE) is 21.01%.

Is STAR a good stock to buy?

This page provides a data-driven analysis of Strides Pharma Science Limited (STAR), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space